Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: A randomized, double-blind and controlled multicenter trial

National Medical Journal of China

Volumn 91, Issue 24, 2011, Pages 1677-1681

  Wang, Ai Hu ^a   Pu, Jie Lin ^b   Qi, Xiao Yong ^b   Miao, Wen Lin ^b   Hou, Zi Shan ^b   Cong, Hong Liang ^b   Zhou, Jian Zhong ^b   Liu, Xiao Fang ^b   Li, Shu Mei ^b   Han, Qing Hua ^b   Liu, Yong Jia ^b   Yang, Xin Chun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Atrial fibrillation; Propafenone; Shensongyangxin capsules

Indexed keywords

CHINESE DRUG; PROPAFENONE; SHENSONGYANXIN; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; HERBACEOUS AGENT; SHENSONGYANGXIN;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHYTOTHERAPY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PHYTOTHERAPY; PROPAFENONE;

EID: 84870509360     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.24.006     Document Type: Article

References (15)

1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population 2 based cohort The Framingham Heart Study. JAMA, 1994, 271: 840-844.
2. 2004, 7: 491-494.
3. I Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace, 2008, 10: 647-665.
4. Bertaglia E, Tondo C, De Simone A, et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentres experience. Europace, 2010, 12: 181-187.
5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006, 114: e257-354.
6. Wyse DG, Waldo AL, Di Marco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 2002, 347: 1825-1833.
7. Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol, 2007, 100: 247-252.
8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med, 2002, 347: 1834-1840.
9. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol, 2003, 41: 1690-1696.
10. 2007, 6: 33-37.
11. Khan R. Identifying and understanding the role of pulmonary vein activity in atrial fibrillation. Cardiovasc Res, 2004, 64: 387-394.
12. Chen YJ, Chen SA, Chen YC, et al. Anhythmogenic activity of cardiac muscle in pulmonary veins of the dog: Implication for the genesis of atrial fibrillation. Cardiovasc Res, 2000, 48: 265-273.
13. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiology breakthroughs from the left atrium to the pulmonary veins. Circulation, 2000, 102: 2463.
14. 1999, 13: 197.
15. 2009, 89: 2142-2146.